Home » Newsletters » BioWorld Science

BioWorld Science

June 11, 2008

View Archived Issues

MORAb-003 shows clinical efficacy in epithelial ovarian cancers

RTA-402 demonstrates antitumor activity and safety in a phase I study

Novel glucokinase activator profiled at Array Biopharma

Promising antiischemic effects of novel Nav1.5 channel blocker F-15845

Synvista Therapeutics reports results of three phase II SYI-2074 trials in diabetic patients

DNA intercalating drug SJG-136 investigated in phase I trials

Avid initiates first phase II trial of 18F-AV-45 for imaging Alzheimer's disease

Raptor receives FDA orphan drug designation for cysteamine in HD

Positive pharmacokinetic findings for novel oral modified release liothyronine

Epigenomics completes study in biomarker lung cancer diagnosis

GlaxoSmithKline acquires Sirtris Pharmaceuticals

Homspera demonstrates adult stem cell activity in human bone marrow

Sygnis Pharma acquires Amnestix

CytRx to acquire Innovive Pharmaceuticals

Recent Merck Frosst patent describes new renin inhibitors for cardiovascular diseases

New antiinflammatory agents reported in recent Abbott patent

Recent Novartis and AstraZeneca patents describe novel agents for respiratory disorders

Second pivotal phase III trial of Dimebon in mild to moderate Alzheimer's disease begins

Phase III PEP-005 trial under SPA agreement with FDA to begin in Q3 2008

Phase IIa proof-of-concept trial of AZ-002 in panic disorder does not meet primary endpoints

Nymox commences phase III NX-1207 program

AstraZeneca submits Seroquel XR in Europe for major depressive disorder

Achillion announces positive top-line phase II elvucitabine data

Shire undertakes voluntary recall of a limited portion of Daytrana patches

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...